$5.10
0.39%
NYSE, Nov 19, 09:32 am EST. Market open.
ISIN
US68218J1034
Symbol
OABI

OmniAb Stock price

$5.08
+0.39 8.32% 1M
+2.79 121.83% 6M
+3.23 174.59% YTD
+3.47 215.53% 1Y
+0.56 12.39% 3Y
-4.89 49.05% 5Y
-4.92 49.20% 10Y
-4.92 49.20% 20Y
NYSE, Closing price Wed, Nov 18 2026
+0.03 0.59%

Is OmniAb a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 9,085 stocks worldwide.

Key metrics

Basic
Market capitalization
$741.0m
Enterprise Value
$676.8m
Net debt
positive
Cash
$64.2m
Shares outstanding
145.9m
Valuation
P/E
negative
P/S | estimate
18.4 | 19.6
EV/Sales | estimate
16.8 | 17.9
EV/FCF | ex SBC
284.4 | negative
P/B
3.0
Financial Health
Equity Ratio
88.7%
Return on Equity
-24.3%
ROCE
-17.0%
ROIC
-21.1%
Debt/Equity
0.0
Share-Based Compensation & Dilution
SBC | % of Revenue
$13.2m | 32.7%
SBC as % of FCF
552.9%
SBC Growth 1Y
-24.1%
Share Count Growth 1Y
1.3%
Shareholder Yield
-1.3%
Financials
Revenue | estimate
$40.2m | $37.8m
EBITDA
$-31.2m
EBIT
$-46.6m
Net Income
$-43.5m
Free Cash Flow | ex SBC
$2.4m | $-10.8m
Growth
Revenue | estimate
90.7% | 102.5%
EBITDA
44.7%
EBIT
35.5%
Net Income
31.7%
Free Cash Flow
106.7%
Margin
Gross
97.7%
EBITDA
-77.7%
EBIT
-115.9%
Net
-108.1%
Free Cash Flow | ex SBC
5.9% | -26.8%
More
EPS
$-0.3
FCF per Share
$0.0
Short interest
6.0%
Employees
89
Rev per Employee
$210.0k

OmniAb Stock Analysis

Unlock Scores for Free

Analyst Opinions

13 Analysts have issued a OmniAb forecast:

12x Buy
92%
1x Hold
8%

Analyst Opinions

13 Analysts have issued a OmniAb forecast:

Buy
92%
Hold
8%

OmniAb Events

Past Events
OCT
30
Q3 2026 Earnings Call
20 days ago
OCT
6
Analyst/Investor Day - OmniAb, Inc.
about one month ago
AUG
6
Q2 2026 Earnings Call
3 months ago
MAY
7
Q1 2026 Earnings Call
7 months ago
MAR
4
Q4 2025 Earnings Call
9 months ago
DEC
15
Special Call - OmniAb, Inc.
11 months ago
NOV
4
Q3 2025 Earnings Call
about one year ago

Financial data from OmniAb

Sep '26
+/-
%
40 40
91% 91%
100%
- Direct Costs 0.94 0.94
224% 224%
2%
39 39
571% 571%
98%
- Selling and Administrative Expenses 27 27
8% 8%
68%
- Research and Development Expense 43 43
9% 9%
106%
-31 -31
45% 45%
-78%
- Depreciation and Amortization 15 15
2% 2%
38%
EBIT (Operating Income) EBIT -47 -47
35% 35%
-116%
Net Profit -43 -43
32% 32%
-108%

In millions USD.

Don't miss a Thing! We will send you all news about OmniAb directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

OmniAb Stock News

Neutral
Business Wire
●
20 days ago
EMERYVILLE, Calif.--(BUSINESS WIRE)---- $OABI #OABI--OmniAb, Inc. (NASDAQ: OABI), a provider of cutting-edge discovery research technology to enable the discovery of next-generation therapeutics, today reported financial results for the three and nine months ended September 30, 2026, provided operating and partner program progress, and updated 2026 financial guidance. “Our strong third-quarter ...
Neutral
Business Wire
●
about one month ago
EMERYVILLE, Calif.--(BUSINESS WIRE)---- $OABI #OABI--OmniAb, Inc. (NASDAQ: OABI), a provider of cutting-edge discovery research technology to enable the discovery of next-generation therapeutics, today hosts its Investor & Analyst Day in Emeryville, CA. With a full presentation agenda, the event highlights recent partner developments, the broader roll out of the xPloration® platform, and introd...
More OmniAb News

Company Profile

OmniAb, Inc. operates as a drug discovery company. It focuses on developing human monoclonal and bispecific therapeutic antibodies. Its platform includes the biological intelligence of its transgenic animals, including OmniRat, OmniChicken and OmniMouse. The company was founded on December 14, 2015 and is headquartered in Emeryville, CA.

Head office United States
CEO Mr. Foehr
Employees 89
Founded 2015
Website www.omniab.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today